Search

Xencor Inc

Open

BrancheGesundheitswesen

29.8 2.69

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

28.16

Max

31.79

Schlüsselkennzahlen

By Trading Economics

Einkommen

107M

-22M

Verkäufe

47M

51M

EPS

-0.29

Gewinnspanne

-42.422

Angestellte

260

EBITDA

109M

-12M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+16.86% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

286M

1.7B

Vorheriger Eröffnungskurs

27.11

Vorheriger Schlusskurs

29.8

Xencor Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Okt. 2026, 23:06 UTC

Xencor Inc shares are trading modestly higher in after-market hours, remaining significantly above their 20-day moving average amid improved economic activity signals.

23. Okt. 2026, 20:02 UTC

Xencor Inc shares fell sharply, reaching a significant low mid-morning before a slight rebound, continuing a downward trend since Thursday.

22. Okt. 2026, 20:07 UTC

Xencor Inc shares advanced, finishing stronger and marking the fifth consecutive day of gains, despite some retracement earlier in the session.

21. Okt. 2026, 21:01 UTC

Xencor Inc is advancing in after-market trading, reaching its highest cumulative return of the day and significantly above its 20-day moving average.

20. Okt. 2026, 20:02 UTC

Event

Xencor Inc will host a webcast on October 26 to discuss Phase 1 Study results of XmAb819 for advanced clear cell renal cell carcinoma.

19. Okt. 2026, 20:07 UTC

News
Event
Social Media

Xencor Inc will host a webcast on October 26 to discuss Phase 1 study results of XmAb819 ahead of the ESMO Congress presentation.

16. Okt. 2026, 20:07 UTC

Correlated Moves

Xencor Inc shares are declining amid a broader downturn in the biotechnology sector, with the SPDR S&P Biotech ETF (XBI) also lower due to negative analyst commentary.

15. Okt. 2026, 19:26 UTC

Correlated Moves

Xencor Inc shares are advancing, supported by gains in the SPDR S&P Biotech ETF following analyst upgrades and positive news from Recursion Pharmaceuticals.

14. Okt. 2026, 22:26 UTC

Xencor Inc shares are trading modestly lower in after-market hours, continuing a downward trend and currently about 5.70% below their 20-day moving average.

13. Okt. 2026, 20:01 UTC

Xencor Inc shares fell sharply, diverging from recent higher daily closes, amid unusually high trading volume today.

9. Okt. 2026, 20:06 UTC

Correlated Moves

Xencor Inc shares are higher, reflecting broader market gains, as the SPDR S&P Biotech ETF rises on news of Moderna's cancer vaccine partnership.

8. Okt. 2026, 20:07 UTC

Xencor Inc shares are modestly higher as the broader market recovers from an earlier low, showing a cumulative return of nearly 0.93%.

6. Okt. 2026, 20:02 UTC

Correlated Moves

Xencor Inc shares fell sharply, influenced by the declining SPDR S&P Biotech ETF amid concerns over inflation risks and dilution from public offerings.

2. Okt. 2026, 19:55 UTC

Xencor Inc shares fell, continuing a four-session decline, after peaking early in the day amid broader weakness in the biotechnology sector.

30. Sept. 2026, 20:07 UTC

News

Shares of Xencor Inc. fell sharply despite Wells Fargo initiating coverage with an Overweight rating and a $55.00 price target.

29. Sept. 2026, 19:46 UTC

Xencor Inc shares fell sharply, showing unusual volatility and dipping nearly 4% since Monday's close before recovering slightly.

28. Sept. 2026, 20:02 UTC

News

Truist Securities raised its price target on Xencor Inc to $29.00, as the stock experiences unusually high volume and continues to gain sharply.

24. Sept. 2026, 19:46 UTC

Xencor Inc shares fell sharply, continuing a downward trend since Wednesday and remaining significantly below its 20-day moving average amid broader market weakness.

23. Sept. 2026, 20:07 UTC

Correlated Moves

Xencor Inc shares fell sharply, reflecting a broader decline linked to significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

22. Sept. 2026, 19:45 UTC

Xencor Inc is modestly higher, continuing positive momentum after four consecutive sessions of gains, despite remaining below its 20-day moving average.

21. Sept. 2026, 20:31 UTC

Xencor Inc. has risen in after-market trading, recovering from an initial dip and reaching a peak notably higher than Monday's close.

17. Sept. 2026, 20:07 UTC

Correlated Moves

Xencor Inc is advancing, likely supported by a rally in the biotechnology sector following positive Phase 3 results for Moderna's cancer vaccine.

16. Sept. 2026, 19:16 UTC

Xencor Inc is trading roughly flat, having fluctuated within a typical range but remains significantly below its 20-day moving average.

15. Sept. 2026, 23:16 UTC

Shares of Xencor Inc. are lower in after-market hours amid broader market pressures and rising yields on the ten-year Treasury note.

10. Sept. 2026, 20:07 UTC

Xencor Inc's shares are lower today, continuing a trend of three consecutive daily declines and trading below the 20-day moving average.

8. Sept. 2026, 20:07 UTC

Xencor Inc shares are trading lower today, following a notable early decline and remaining below their 20-day moving average. No specific news was identified.

4. Sept. 2026, 20:07 UTC

Xencor Inc shares are higher, recovering from earlier losses amid broader market selling pressure following a strong jobs report. No specific news was identified.

3. Sept. 2026, 22:15 UTC

News

Shares lower in after-market trading after JP Morgan's rating.

2. Sept. 2026, 20:08 UTC

Xencor Inc shares are lower today, reversing from an early gain amid a weaker-than-expected ADP employment report affecting investor sentiment on interest rates.

1. Sept. 2026, 23:01 UTC

Xencor Inc shares are lower in after-market hours, with no specific news identified. This decline occurs amid broader market concerns over economic growth data.

Peer-Vergleich

Kursveränderung

Xencor Inc Prognose

Kursziel

By TipRanks

16.86% Vorteil

12-Monats-Prognose

Durchschnitt 34.1 USD  16.86%

Hoch 46 USD

Tief 20 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Xencor Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

11

Buy

2

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat